IP Library Granted Patent US 12,263,116
Granted Patent B2
US 12,263,116 · App. 17/166,619 · Granted Apr 1, 2025

Dry eye treatment systems

Inventor: Paul Badawi (Menlo Park, CA)
Assignee: Sight Sciences, Inc.
A61F7/007A61F7/02A61F9/0008A61F9/0017A61F13/124A61M37/00A61F2007/0004A61F2007/0075A61F2007/0078A61F2007/0086A61F2007/0093A61F2007/0094A61F2007/0095A61F2007/0096A61F2007/0226A61F2007/0242A61F2007/0244A61M35/10A61M2037/0007A61M2205/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,116
App. No.
17/166,619
Granted
Apr 1, 2025
Kind
B2
Abstract

Dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and/or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. Moreover, the one or more strips may be configured to emit energy to the underlying region of skin and where the one or more strips are shaped to follow a location of one or more meibomian glands contained within the underlying region of skin.

Claims (35)

1. A treatment system comprising:

a controller;

a connecting cable; and

a strip attachable to a first eyelid and to a second eyelid, wherein the strip has an open first end and a closed second end, wherein the open first end is opposite the closed second end, and wherein energy is emittable to the first eyelid and/or to the second eyelid via the strip,

wherein the open first end comprises a first portion and a second portion separated by a gap, wherein the gap is configured to be larger when a person has their eyes open than when the person has their eyes closed,

wherein when the treatment system is in an assembled configuration, the connecting cable extends from the closed second end and connects the strip to the controller,

wherein a treatment therapy is controllable via the controller, and

wherein the strip has a thickness of up to 3.175 mm such that the first eyelid and/or the second eyelid are allowed to blink naturally without restriction from the strip.

2. The treatment system of claim 1 , wherein the open first end is configured for placement on the first and second eyelids, and wherein the closed second end is configured for placement between the first and second eyelids.

3. The treatment system of claim 2 , wherein the open first end is configured for placement between a lateral canthus and a nose.

4. The treatment system of claim 3 , wherein the open first end is configured for placement between the lateral canthus and a medial canthus.

5. The treatment system of claim 3 , wherein the closed second end is configured for placement between the lateral canthus and an ear.

6. The treatment system of claim 2 , wherein the closed second end is configured for placement between a lateral canthus and an ear.

7. The treatment system of claim 6 , wherein the open first end is configured for placement between the lateral canthus and a nose.

8. The treatment system of claim 7 , wherein the open first end is configured for placement between the lateral canthus and a medial canthus.

9. The treatment system of claim 1 , wherein the first portion is configured for placement on the first eyelid, the second portion is configured for placement on the second eyelid, and the gap is configured for placement between the first and second eyelids.

10. The treatment system of claim 1 , wherein the first portion has a different shape than the second portion.

11. The treatment system of claim 1 , wherein energy is controllably emittable from the strip to the first eyelid and/or to the second eyelid via the controller.

12. The treatment system of claim 1 , wherein the first portion has a curved or arcuate periphery which is shaped to extend and follow a free margin of the first eyelid, and wherein the second portion has a curved or arcuate periphery which is shaped to extend and follow a free margin of the second eyelid.

13. The treatment system of claim 1 , wherein the strip comprises a compressive mechanism configured to apply a biasing force to one or more meibomian glands, and wherein the compressive mechanism is configured for application to the one or more meibomian glands during emission of the energy to the first eyelid and/or to the second eyelid.

14. The treatment system of claim 1 , further comprising an electronic device configured to allow a user to test for dry eye and/or to determine how treatment is progressing before, during, or after the treatment therapy.

15. A treatment system comprising:

a cable;

a strip attachable to a first eyelid and to a second eyelid, wherein the strip has a first arm, a second arm, and a third arm, wherein the first arm and the second arm are opposite the third arm, wherein the cable extends from the third arm to a controller, and wherein energy is emittable to the first eyelid and/or to the second eyelid via the strip,

wherein the strip has flexibility sufficient to accommodate movement of the first eyelid to allow for a subject to blink naturally without restriction from the strip while covering one or more meibomian glands contained within the first eyelid with the strip, and

wherein energy is emittable to the first eyelid via the first arm and/or to the second eyelid via the second arm.

16. The treatment system of claim 15 , wherein the first arm, the second arm, and the third arm extend from a junction.

17. The treatment system of claim 16 , wherein the junction is configured for placement between a lateral canthus and an ear, or wherein the first arm and the second arm are configured to be placed closer to a nose than the third arm.

18. The treatment system of claim 15 , wherein the first arm and/or the second arm have a thickness of up to 3.175 mm such that the first eyelid and/or the second eyelid are allowed to blink naturally without restriction from the strip.

19. A treatment system comprising:

a strip attachable to a first eyelid and/or to a second eyelid, wherein the strip comprises a first arm, a second arm, and a third arm, wherein the first arm and the second arm are opposite the third arm, wherein the first arm and the second arm are separated by a gap, wherein when the strip is worn by a person, the gap is larger when the person has their eyes open than when the person has their eyes closed, wherein energy is emittable to the first eyelid and/or to the second eyelid via the strip,

wherein the first arm, the second arm, and the third arm extend from a junction,

wherein the first arm and/or the second arm have a thickness of up to 3.175 mm such that the first eyelid and/or the second eyelid are allowed to blink naturally without restriction from the strip, and

wherein the third arm comprises a cable.

20. The treatment system of claim 19 , wherein the cable extends from the third arm to a controller.

Assignments (2)
SECURITY INTEREST Recorded Jan 23, 2024
From: SIGHT SCIENCES, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 066364/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2021
From: BADAWI, PAUL
To: SIGHT SCIENCES, INC.
Reel/Frame 055133/0857 →
Continuity (6)
Continuation 16059281 · Aug 9, 2018
Continuation 15442003 · Feb 24, 2017
Continuation 15364070 · Nov 29, 2016
Continuation 13645985 · Oct 5, 2012
Continuation In Part 13343407 · Jan 4, 2012
Related Publication 20210177647A1 · Jun 17, 2021
References Cited (199)
US 2001862A · Carter · 1935 [cited by applicant]
US 2108934A · Albright · 1938 [cited by applicant]
US 2635175A · Hodge · 1953 [cited by applicant]
US 3075527A · Bechtold · 1963 [cited by applicant]
US 3173419A · Dublier et al. · 1965 [cited by applicant]
US 3589369A · Alksnis · 1971 [cited by applicant]
US 4096864A · Kletschka et al. · 1978 [cited by applicant]
US 4261364A · Haddad et al. · 1981 [cited by applicant]
US 4325254A · Svacina et al. · 1982 [cited by applicant]
US 4867146A · Krupnick et al. · 1989 [cited by applicant]
US 4930317A · Klein · 1990 [cited by applicant]
US 4962761A · Golden · 1990 [cited by applicant]
US 5097829A · Quisenberry · 1992 [cited by applicant]
US 5164987A · Raven · 1992 [cited by applicant]
US 5169384A · Bosniak et al. · 1992 [cited by applicant]
US 5643336A · Lopez-Claros · 1997 [cited by applicant]
US 5860985A · Anschutz · 1999 [cited by applicant]
US 6066164A · Macher et al. · 2000 [cited by applicant]
US 6074414A · Haas et al. · 2000 [cited by applicant]
US 6155995A · Lin · 2000 [cited by applicant]
US 6193741B1 · Heavenridge et al. · 2001 [cited by applicant]
US D441081S · Mueller · 2001 [cited by applicant]
US 6238427B1 · Matta · 2001 [cited by applicant]
US 6409746B1 · Igaki et al. · 2002 [cited by applicant]
US 6416534B1 · Montagnino et al. · 2002 [cited by applicant]
US 6511446B1 · Wu · 2003 [cited by applicant]
US 6860880B2 · Treat et al. · 2005 [cited by applicant]
US 6908195B2 · Fuller, Jr. · 2005 [cited by applicant]
US D507054S · Mueller et al. · 2005 [cited by applicant]
US D507055S · Mueller et al. · 2005 [cited by applicant]
US D507350S · Mueller et al. · 2005 [cited by applicant]
US D507651S · Mueller et al. · 2005 [cited by applicant]
US 6923988B2 · Patel et al. · 2005 [cited by applicant]
US D511573S · Mueller et al. · 2005 [cited by applicant]
US D513323S · Mueller et al. · 2005 [cited by applicant]
US 7069084B2 · Yee · 2006 [cited by applicant]
US 7108694B2 · Miura et al. · 2006 [cited by applicant]
US 7211070B2 · Soroudi · 2007 [cited by applicant]
US 7229468B2 · Wong, Jr. et al. · 2007 [cited by applicant]
US D613408S · Gausmann et al. · 2010 [cited by applicant]
US D614303S · Gausmann et al. · 2010 [cited by applicant]
US D614774S · Gausmann et al. · 2010 [cited by applicant]
US D617443S · Grenon et al. · 2010 [cited by applicant]
US 7758190B2 · Korb et al. · 2010 [cited by applicant]
US 7833205B2 · Grenon et al. · 2010 [cited by applicant]
US D638128S · Prokop et al. · 2011 [cited by applicant]
US 7976573B2 · Korb et al. · 2011 [cited by applicant]
US 7981095B2 · Grenon et al. · 2011 [cited by applicant]
US 7981145B2 · Korb et al. · 2011 [cited by applicant]
US 7981146B2 · Korb et al. · 2011 [cited by applicant]
US 7981147B2 · Korb et al. · 2011 [cited by applicant]
US 7988294B2 · Korb et al. · 2011 [cited by applicant]
US 8007524B2 · Korb et al. · 2011 [cited by applicant]
US 8025689B2 · Korb et al. · 2011 [cited by applicant]
US 8506539B2 · Guillon et al. · 2013 [cited by applicant]
US 8535363B1 · Lewis · 2013 [cited by applicant]
US 8685073B2 · Korb et al. · 2014 [cited by applicant]
US 8950405B2 · Grenon et al. · 2015 [cited by applicant]
US 8960204B2 · Samain et al. · 2015 [cited by applicant]
US 9510972B2 · Badawi · 2016 [cited by examiner]
US 9642743B2 · Badawi · 2017 [cited by applicant]
US 9724230B2 · Badawi · 2017 [cited by examiner]
US 9844459B2 · Badawi · 2017 [cited by applicant]
US 10052226B2 · Badawi et al. · 2018 [cited by applicant]
US 10772758B2 · Badawi · 2020 [cited by examiner]
US 10925765B2 · Badawi · 2021 [cited by examiner]
US 10973680B2 · Badawi et al. · 2021 [cited by applicant]
US 11285040B2 · Badawi et al. · 2022 [cited by applicant]
US 20020117495A1 · Kochman et al. · 2002 [cited by applicant]
US 20020180929A1 · Tseng et al. · 2002 [cited by applicant]
US 20030167556A1 · Kelley · 2003 [cited by applicant]
US 20030236487A1 · Knowlton · 2003 [cited by applicant]
US 20040044384A1 · Leeber et al. · 2004 [cited by applicant]
US 20040116990A1 · Agarwal et al. · 2004 [cited by applicant]
US 20040237969A1 · Fuller · 2004 [cited by applicant]
US 20050119629A1 · Soroudi · 2005 [cited by applicant]
US 20050159775A1 · Reynolds · 2005 [cited by applicant]
US 20050187502A1 · Krempel · 2005 [cited by examiner]
US 20060018953A1 · Guillon et al. · 2006 [cited by applicant]
US 20060069420A1 · Rademacher et al. · 2006 [cited by applicant]
US 20060154642A1 · Scannell · 2006 [cited by applicant]
US 20060200052A1 · Lin · 2006 [cited by applicant]
US 20060219701A1 · Kil · 2006 [cited by applicant]
US 20060235497A1 · Zanotti · 2006 [cited by applicant]
US 20070016255A1 · Korb et al. · 2007 [cited by applicant]
US 20070060988A1 · Grenon et al. · 2007 [cited by applicant]
US 20080039749A1 · Kopanic et al. · 2008 [cited by applicant]
US 20080039769A1 · Peyman · 2008 [cited by applicant]
US 20080081999A1 · Gravely · 2008 [cited by examiner]
US 20080109053A1 · Grenon et al. · 2008 [cited by applicant]
US 20080114421A1 · Korb et al. · 2008 [cited by applicant]
US 20080114423A1 · Grenon et al. · 2008 [cited by applicant]
US 20080114424A1 · Grenon et al. · 2008 [cited by applicant]
US 20080132978A1 · Korb et al. · 2008 [cited by applicant]
US 20080132987A1 · Westlund et al. · 2008 [cited by applicant]
US 20080269850A1 · Dodo · 2008 [cited by applicant]
US 20090020521A1 · Blaszczykiewicz et al. · 2009 [cited by applicant]
US 20090048590A1 · Conrad et al. · 2009 [cited by applicant]
US 20090123886A1 · Vaska · 2009 [cited by applicant]
US 20090137533A1 · Adkins, Jr. · 2009 [cited by applicant]
US 20090149925A1 · MacDonald et al. · 2009 [cited by applicant]
US 20090199571A1 · Creech et al. · 2009 [cited by applicant]
US 20090312823A1 · Patience et al. · 2009 [cited by applicant]
US 20100010598A1 · Igaki et al. · 2010 [cited by applicant]
US 20100114086A1 · Deem et al. · 2010 [cited by applicant]
US 20100172567A1 · Prokoski · 2010 [cited by applicant]
US 20100174501A1 · Myadam · 2010 [cited by applicant]
US 20100198282A1 · Rogers · 2010 [cited by applicant]
US 20100217360A1 · Henriksson et al. · 2010 [cited by applicant]
US 20100267751A1 · Beals et al. · 2010 [cited by applicant]
US 20100286654A1 · Dos Santos et al. · 2010 [cited by applicant]
US 20110046581A1 · Linder · 2011 [cited by applicant]
US 20110081333A1 · Shantha et al. · 2011 [cited by applicant]
US 20110198282A1 · Chu et al. · 2011 [cited by applicant]
US 20110275410A1 · Caffey et al. · 2011 [cited by applicant]
US 20120062840A1 · Ballou et al. · 2012 [cited by applicant]
US 20120191164A1 · Gander et al. · 2012 [cited by applicant]
US 20120213840A1 · Lim · 2012 [cited by applicant]
US 20120222192A1 · Carey et al. · 2012 [cited by applicant]
US 20130046367A1 · Chen · 2013 [cited by applicant]
US 20130083184A1 · Yogesan et al. · 2013 [cited by applicant]
US 20130172790A1 · Badawi · 2013 [cited by applicant]
US 20130172829A1 · Badawi · 2013 [cited by applicant]
US 20130281893A1 · Yang · 2013 [cited by applicant]
US 20140052198A1 · Mohn et al. · 2014 [cited by applicant]
US 20140276248A1 · Hall et al. · 2014 [cited by applicant]
US 20140303694A1 · Timme et al. · 2014 [cited by applicant]
US 20140316314A1 · Schubert · 2014 [cited by applicant]
US 20140330129A1 · Grenon et al. · 2014 [cited by applicant]
US 20150025545A1 · Grenon et al. · 2015 [cited by applicant]
US 20150216725A1 · Korb et al. · 2015 [cited by applicant]
US 20160045755A1 · Chun et al. · 2016 [cited by applicant]
US 20160100977A1 · Lee et al. · 2016 [cited by applicant]
US 20160106576A1 · Badawi et al. · 2016 [cited by applicant]
US 20160106775A1 · Alster et al. · 2016 [cited by applicant]
US 20160317379A1 · Mosaddegh · 2016 [cited by applicant]
US 20170014300A1 · Dippo et al. · 2017 [cited by applicant]
US 20170079834A1 · Badawi · 2017 [cited by applicant]
US 20170079840A1 · Badawi · 2017 [cited by applicant]
US 20170087009A1 · Badawi et al. · 2017 [cited by applicant]
US 20170165106A1 · Badawi · 2017 [cited by applicant]
US 20170188805A1 · Pradeep · 2017 [cited by applicant]
US 20170273823A1 · Novkov et al. · 2017 [cited by applicant]
US 20170304110A1 · Badawi · 2017 [cited by applicant]
US 20180071140A1 · Sheydin · 2018 [cited by applicant]
US 20180200494A1 · Gatrall et al. · 2018 [cited by applicant]
US 20180344512A1 · Badawi · 2018 [cited by applicant]
US 20190274873A1 · Schoeggler · 2019 [cited by applicant]
US 20200078032A1 · Nanda et al. · 2020 [cited by applicant]
US 20200078211A1 · Badawi et al. · 2020 [cited by applicant]
US 20200188169A1 · McMahon · 2020 [cited by applicant]
US 20210022914A1 · Badawi et al. · 2021 [cited by applicant]
US 20210052216A1 · Badawi · 2021 [cited by applicant]
US 20210169682A1 · Alvarez et al. · 2021 [cited by applicant]
US 20210177648A1 · Badawi et al. · 2021 [cited by applicant]
US 20220168136A1 · Badawi et al. · 2022 [cited by applicant]
CN 202313590 · 2012 [cited by applicant]
CN 103417306 · 2013 [cited by applicant]
CN 203493672 · 2014 [cited by applicant]
CN 203564408 · 2014 [cited by applicant]
CN 205234758 · 2016 [cited by applicant]
CN 205568977 · 2016 [cited by applicant]
DE 29920352 · 2000 [cited by applicant]
JP 1995185017 · 1995 [cited by applicant]
JP 3071816 · 2000 [cited by applicant]
JP 2003093431 · 2003 [cited by applicant]
JP 2007520A · 2007 [cited by applicant]
JP 2007185017 · 2007 [cited by applicant]
JP 2007229175A · 2007 [cited by applicant]
JP 2010504769 · 2010 [cited by applicant]
JP 2010515481 · 2010 [cited by applicant]
JP 2011188958 · 2011 [cited by examiner]
JP 3170844 · 2011 [cited by applicant]
JP 2015503417 · 2015 [cited by applicant]
JP 2015527122 · 2015 [cited by applicant]
JP 2020199386 · 2020 [cited by applicant]
KR 200301311 · 2003 [cited by applicant]
KR 20100002818 · 2010 [cited by applicant]
WO WO1994011739 · 1994 [cited by applicant]
WO WO1999020213 · 1999 [cited by applicant]
WO WO2000069506 · 2000 [cited by applicant]
WO WO2002067688 · 2002 [cited by applicant]
WO WO2004006801 · 2004 [cited by applicant]
WO WO2006099413 · 2006 [cited by applicant]
WO WO2007102362A1 · 2007 [cited by examiner]
WO WO2008085162 · 2008 [cited by applicant]
WO WO2008100647 · 2008 [cited by applicant]
WO WO2013103413 · 2013 [cited by applicant]
WO WO2016070134 · 2016 [cited by applicant]
WO WO2017100608 · 2017 [cited by applicant]
WO WO2020055634 · 2019 [cited by applicant]
WO WO2021026154 · 2021 [cited by applicant]
Lee (OD shares drug-free approach to treating meibomian gland dysfunction, Jeanette Lee, https://www.healio.com/news/optometry/20120225/od-shares-drug-free-approach-to-treating-meibomian-gland-dysfunction, accessed: Jun… [cited by examiner]
Blackie, Caroline A. et al., “Inner Eyelid Surface Temperature as a Function of Warm Compress Methodology,” [cited by applicant]
Bron, A.J. et al., “Functional Aspects of the Tear Film Lipid Layer,” [cited by applicant]
Driver, Paul J. et al., “Meibomian Gland Dysfunction,” [cited by applicant]
Gifford, Sanford R., “Meibomian Glands in Chronic Blepharo-Conjunctivitis,” [cited by applicant]
Goto, E et al., “Treatment of Non-Inflamed Obstructive Meibomian Gland Dysfunction by an Infrared Warm Compression Device,” [cited by applicant]
Olson, Mary Catherine et al., “Increase in Tear Film Lipid Layer Thickness Following Treatment with Warm Compresses in Patients with Meibomian Gland Dysfunction,” [cited by applicant]